581-50-0

Applied Filters:

Keyword:'581-50-0'

Showing 1-1 of 1 result for "581-50-0" within Papers

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Gunter von Minckwitz et al.

The Lancet. Oncology, 15(7), 747-756 (2014-05-06)

Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy

Page 1 of 1